🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms

RecruitingNAAges 18 Years - 90 YearsFemaleSichuan Cancer Hospital and Research Institute
NCT05526534 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with gynecologic Neoplasms, including benign gynecologic tumors and malignant gynecologic tumors, who are 18 to 90 years old and are scheduled for surgical treatment in our center shall receive plain chest CT scan within 1 week before surgery, and the estimated surgical time shall be ≥2 hours, and at least one of the following conditions shall be met: 1. Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points; 2. BMI≥30; 3. Moderate to severe asthma; 4. Moderate to severe chronic obstructive pulmonary disease (COPD); 5. Smoking history ≥20 packs/year Exclusion Criteria: 1. Patients with lung metastasis of malignant tumor or primary lung malignant tumor; 2. previous lung surgery or radiotherapy; 3. the surgery involved segmental bowel resection.
💊

What it tests

  • heated humidified high flow nasal cannula oxygen therapy, HFNC
  • Nasal cannula oxygen
📍

Where

1 site
Sichuan Cancer Hospital and Research Institute
Chengdu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy